Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Amiloride in Nephrotic Syndrome
NCT05079789 · University Hospital Tuebingen · PHASE3 · terminated · last registry update 2025-01-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruiting rate and decision to evaluate as pilot study” | – | Registry record, University Hospital Tuebingen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCNN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-30Results posted on the registry: University of Missouri-Columbia, Placebo - Cap + Amiloride Pill (NCT03837626)
- 2025-06-12Results posted on the registry: Eurofarma Laboratorios S.A., Chlorthalidone 25 mg + amiloride hydrochloride 5 mg + Higroton® Laboratório Novartis (NCT01191450)
- 2024-05-16Phase 3 first posted: Ospedale San Raffaele, Amiloride (NCT06416735)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision